相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatitis C Virus Gene Sequencing as a Tool for Precise Genotyping in the Era of New Direct Antiviral Agents
Francesca Ceccherini Silberstein et al.
HEPATOLOGY (2016)
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
Christoph Sarrazin et al.
ANTIVIRAL RESEARCH (2015)
Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C
Anita Y. M. Howe et al.
ANTIVIRAL RESEARCH (2015)
901f Efficacy and Safety of Grazoprevir/Elbasvir ± Ribavirin (RBV) for 12 or 16 Weeks in Patients With HCV G1, G4, or G6 Infection Who Previously Failed Peginterferon/RBV: C-EDGE Treatment-Experienced Trial
Paul Y Kwo et al.
GASTROENTEROLOGY (2015)
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
Erik Lontok et al.
HEPATOLOGY (2015)
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Raymond T. Chung et al.
HEPATOLOGY (2015)
Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
Andrew J. Muir et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping
Chen-Hua Liu et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2015)
Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort
Samantha J. Shepherd et al.
JOURNAL OF CLINICAL VIROLOGY (2015)
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma
Dante Romagnoli et al.
JOURNAL OF CLINICAL VIROLOGY (2015)
A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE OR -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS: OPTIMIST-2
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
RETREATMENT OF PATIENTS WHO FAILED 8 OR 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR- BASED REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24 WEEKS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2015)
Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
Fred Poordad et al.
CLINICAL INFECTIOUS DISEASES (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
Update on hepatitis C virus resistance to direct-acting antiviral agents
Eva Poveda et al.
ANTIVIRAL RESEARCH (2014)
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
Maximilian David Schneider et al.
ANTIVIRAL RESEARCH (2014)
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2014)
The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: A 1 year analysis
Marlin Benedet et al.
JOURNAL OF CLINICAL VIROLOGY (2014)
Evaluation of the Abbott RealTime HCV genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing
Melanie A. Mallory et al.
JOURNAL OF CLINICAL VIROLOGY (2014)
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
D. L. Wyles et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al.
LANCET (2014)
HCV direct-acting antiviral agents: the best interferon-free combinations
Raymond Schinazi et al.
LIVER INTERNATIONAL (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy
Valeria Cento et al.
ANTIVIRAL THERAPY (2013)
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
James C. Sullivan et al.
CLINICAL INFECTIOUS DISEASES (2013)
Sequencing Assays for Failed Genotyping with the Versant Hepatitis C Virus Genotype Assay (LiPA), Version 2.0
Sylvie Larrat et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
Yoshiyasu Karino et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Doug J. Bartels et al.
JOURNAL OF VIROLOGY (2013)
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz et al.
LANCET INFECTIOUS DISEASES (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The role of resistance in HCV treatment
Johannes Vermehren et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Treatment failure with new hepatitis C drugs
Vincent Soriano et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
Fred Poordad et al.
GASTROENTEROLOGY (2012)
Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients
Hiroko Shindo et al.
HEPATOLOGY INTERNATIONAL (2012)
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy
Ilaria Vicenti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS
E. J. Gane et al.
JOURNAL OF HEPATOLOGY (2012)
Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method
Bernard Besse et al.
JOURNAL OF VIROLOGICAL METHODS (2012)
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naive and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
Tara L. Kieffer et al.
PLOS ONE (2012)
HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors
Valeria Cento et al.
PLOS ONE (2012)
Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
P. Trimoulet et al.
HIV MEDICINE (2011)
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
Simone Susser et al.
JOURNAL OF CLINICAL VIROLOGY (2011)
MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods
Koichiro Tamura et al.
MOLECULAR BIOLOGY AND EVOLUTION (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice
Stephane Chevaliez et al.
PLOS ONE (2009)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Caloramator viterbensis sp nov., a novel thermophilic, glycerol-fermenting bacterium isolated from a hot spring in Italy
M Seyfried et al.
INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
分享论文
